We're taking a closer look at BioMarin Pharmaceutical today, as the chatter surrounding the stock has increased notably in the last few weeks. Today, its shares moved 12.2% compared to 0.0% for the S&P 500. Increased investor interest and volatility surrounding the stock are not reason enough to buy in -- you should first perform your own due diligence. Here are some figures that can get you started:
-
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions.
-
BioMarin Pharmaceutical has moved 5.0% over the last year compared to 15.0% for the S&P 500 -- a difference of -10.0%
-
BMRN has an average analyst rating of buy and is -26.9% away from its mean target price of $116.95 per share
-
Its trailing 12 month earnings per share (EPS) is $0.77
-
BioMarin Pharmaceutical has a trailing 12 month Price to Earnings (P/E) ratio of 111.0 while the S&P 500 average is 15.97
-
Its forward earnings per share (EPS) is $2.41 and its forward P/E ratio is 35.5
-
BMRN has a Price to Earnings Growth (PEG) ratio of 1.4, which shows the company is fairly valued compared to its earnings.
-
The company has a Price to Book (P/B) ratio of 3.29 in contrast to the S&P 500's average ratio of 2.95
-
BioMarin Pharmaceutical is part of the Health Care sector, which has an average P/E ratio of 24.45 and an average P/B of 4.16
-
BioMarin Pharmaceutical has on average reported free cash flows of $10.66 Million over the last four years, during which time they have grown by an an average of 5.8%